RecruitingMild Cognitive Impairment (MCI)
Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
Eligible age
55–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Sponsor: Pravat Mandal
You may qualify if…
- ✓ 1. Memory complaints;
- ✓ 2. MCI diagnosis
- ✓ 3. MoCA score between 18-25
- ✓ 4. Age 55 - 80 years old.
- ✓ 5. Ability to read and write in English
You may not qualify if…
- ✕ 1. Subjects with acute head trauma or head injury involving loss of consciousness;
- ✕ 2. Subjects with a history of cancer;
- ✕ 3. Subjects with a history of schizophrenia, manic-depressive disorder
- ✕ 4. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)
- ✕ 5. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse/dependence;
Where it's recruiting
Pennsylvania
Pittsburgh
Source: ClinicalTrials.gov · NCT07583251 · last updated 2026-06-03